Carbon-14 Radiosynthesis Services Research:CAGR of 5.3% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Carbon-14 Radiosynthesis Services- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Carbon-14 Radiosynthesis Services market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Carbon-14 Radiosynthesis Services was estimated to be worth US$ 228 million in 2025 and is projected to reach US$ 326 million, growing at a CAGR of 5.3% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6115602/carbon-14-radiosynthesis-services

Carbon-14 Radiosynthesis Services Product Introduction

Carbon-14 Radiosynthesis Services refer to specialized technical services that design and execute the synthesis of compounds labeled with the radioactive isotope carbon-14 (14C) for scientific research, drug development, and industrial applications. These services, typically offered by contract research organizations (CROs), academic research institutions, or specialized biotech service providers, follow custom-tailored workflows: they first select appropriate 14C precursors (e.g., sodium acetate-1-14C, potassium cyanide-14C) based on the target compound's structure and client needs, then use chemical reactions like carbon-carbon bond formation, oxidation, or reduction to covalently incorporate 14C into specific positions of the molecule-ensuring the isotope's stability and retention throughout the synthesis process. Ultimately, the 14C-labeled compounds produced through these services enable clients (pharmaceutical companies, research labs, environmental agencies) to track molecular pathways, study long-term drug absorption, distribution, metabolism, and excretion (ADME) in preclinical and clinical studies, or analyze environmental pollutant degradation and carbon cycling in ecological research.

According to the new market research report "Global Carbon-14 Radiosynthesis Services Market Report 2025-2031", published by QYResearch, the global Carbon-14 Radiosynthesis Services market size is projected to reach USD 0.31 billion by 2031, at a CAGR of 5.3% during the forecast period.

Figure00001. Global Carbon-14 Radiosynthesis Services Market Size (US$ Million), 2025 VS 2031

Carbon-14 Radiosynthesis Services

Above data is based on report from QYResearch: Global Carbon-14 Radiosynthesis Services Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

Figure00002. Global Carbon-14 Radiosynthesis Services Top 12 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)

Carbon-14 Radiosynthesis Services

Above data is based on report from QYResearch: Global Carbon-14 Radiosynthesis Services Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Carbon-14 Radiosynthesis Services include Eurofins, Revvity, Selcia, Novandi Chemistry, Almac, Pharmaron, WuXi AppTec, AM Chemicals, Nuvisan, Alfa Cytology, etc. Carbon-14 radiosynthesis service providers are concentrated in North America and Western Europe, with a strong and growing base in East Asia, because these regions combine dense pharma/CRO ecosystems, licensed radiochemistry facilities with GMP/GLP quality systems, reliable access to radioisotope supply chains and compliant waste-handling infrastructure, and deep pools of experienced radiochemists and regulatory know-how that speed complex custom labeling from route design to release testing.

Table 1. Carbon-14 Radiosynthesis Services Industry Chain Analysis

Item

Description

Upstream

Core inputs enabling Carbon-14 radiosynthesis

14C isotope feedstock (e.g., [14C]-carbon dioxide, [14C]-labeled precursors) from specialized isotope suppliers; radiochemical-grade reagents/solvents (compatible with radioactive synthesis); radiation-shielded equipment (shielded reaction vessels, radioactivity detectors); radiation safety materials (protective gear, containment systems); and regulatory licensing (for handling radioactive substances).

Midstream

Core service operations

Provided by specialized radiochemistry CROs/labs; includes custom [14C]-labeling of target compounds (small molecules, biopharmaceuticals, agrochemicals) via techniques (e.g., [14C]-carboxylation, methylation); GMP-compliant synthesis scaling; quality control (verifying radiochemical purity, specific radioactivity, chemical identity); and regulatory documentation (for preclinical/clinical/agrochemical study submissions).

Downstream

Medical

Pharmaceutical enterprises using [14C]-labeled compounds for ADME-Tox (absorption/distribution/metabolism/excretion/toxicity) studies in preclinical/clinical drug development; academic medical research on drug metabolism pathways and disease mechanism tracing.

Chemical Research

Academic/industrial chemistry labs leveraging [14C] tracers for reaction mechanism validation, catalyst performance evaluation; material science research (e.g., polymer degradation pathway tracing) to optimize chemical product stability.

Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025

Table 2. Carbon-14 Radiosynthesis Services Industry Policy Analysis

Policy

Description

1

U.S. NRC 2024: Streamlined Licensing for Low-Risk 14C Radiochemistry Facilities

In 2024, the U.S. Nuclear Regulatory Commission (NRC) updated its radioactive material licensing rules for facilities handling low-specific-activity Carbon-14 (14C). The policy simplifies approval for 14C radiosynthesis labs (classifying 14C as "low-risk" for non-high-volume use), cutting licensing timelines from 12+ months to ~6 months. This reduces barriers to entry for small/mid-sized 14C service providers and accelerates capacity expansion for preclinical R&D support.

2

EU 2023: Euratom Radiation Protection Amendment (Council Directive 2023/2300)

Enacted in 2023, this EU policy updates occupational radiation safety standards for 14C synthesis facilities. It mandates real-time radiation dose monitoring systems for personnel and enhanced containment protocols for 14C-labeled waste during synthesis. For 14C radiosynthesis services, this requires facility upgrades (e.g., installing automated shielding/detection tools) but also standardizes safety practices across EU member states, reducing cross-border compliance costs for service providers.

3

China NNSA 2025: 14C Isotope Self-Sufficiency & Clinical-Grade GMP Mandate

In 2025, China's National Nuclear Safety Administration (NNSA) issued a policy targeting 14C radiosynthesis: (1) Requiring 70% domestic supply of 14C precursors (e.g., [14C]-CO2) by 2028 (reducing reliance on imports); (2) Mandating that domestic 14C services meet CFDA's GMP standards for clinical-grade labeled compounds. This policy boosts demand for local 14C radiosynthesis providers and aligns their services with global regulatory requirements for drug development.

4

U.S. FDA 2024: Guidance on 14C-Labeled Biopharmaceutical Tracers

Released in 2024, the FDA's updated guidance clarifies GMP requirements for 14C-labeled biologic (e.g., antibody) tracers used in ADME studies. It allows "flexible GMP scopes" for early-phase biopharma research (reducing overhead for 14C synthesis services while maintaining safety benchmarks). This policy expands demand for 14C radiosynthesis services in biopharmaceutical R&D, as more firms use 14C tracers to study large-molecule drug metabolism.

Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025

Table 3. Carbon-14 Radiosynthesis Services Industry Development Trends

Development Trends

Description

1

Site-Specific 14C Labeling for Biopharmaceuticals & Large Molecules

As biopharmaceuticals (antibodies, ADCs, gene therapies) grow in drug development, 14C radiosynthesis services are shifting to site-specific 14C labeling (vs. non-specific methods) for large-molecule tracers. This uses chemoenzymatic synthesis to target specific functional groups, boosting radiochemical purity (≥98%) and reducing background noise in ADME studies. Providers are expanding capabilities for 14C-labeled biologic tracers-a segment projected to grow at 12% CAGR (2025-2030).

2

Automated, High-Throughput 14C Synthesis Platforms

To meet rising R&D demand, service providers are deploying fully automated, radiation-shielded 14C synthesis systems (robotic reactors, closed-loop purification). These cut manual labor by 60%, lower radiation exposure risk, and enable high-throughput production (10+ custom 14C compounds/day, up from 2-3 previously). Real-time QC integration (online HPLC-radioactivity detectors) shortens turnaround times to 5-7 days for routine orders.

3

Expansion into Non-Pharma Application Domains

Beyond pharmaceutical ADME-Tox, 14C radiosynthesis services are expanding into emerging sectors: 1) Advanced materials (14C-labeled polymers to trace sustainable packaging degradation); 2) Environmental science (14C tracers for microplastic fate monitoring); 3) Industrial chemistry (14C-labeled catalysts to validate reaction mechanisms). Agrochemical demand (14C environmental fate studies for regulatory approval) also drives growth in this trend.

4

Regional Capacity Localization & Global Regulatory Harmonization

To mitigate supply chain delays (e.g., cross-border 14C isotope transport) and meet regional mandates (e.g., China's 2025 14C self-sufficiency policy), 14C synthesis capacity is localizing (new labs in India, Southeast Asia). Providers are also aligning services with global standards (FDA GMP, EU EMA guidelines) to offer "globally compliant" 14C compounds-letting clients use the same material across multi-region trials, reducing redundant testing costs.

Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025

Table 4. Carbon-14 Radiosynthesis Services Industry Development Opportunities

Development Opportunities

Description

1

Site-Specific 14C Labeling for Biopharmaceutical R&D

Biopharmaceuticals (antibodies, ADCs, gene therapies) require precise, site-specific 14C labeling for ADME-Tox studies-but current industry capacity for large-molecule 14C synthesis is limited. Service providers can capture high-margin market share by expanding specialized chemoenzymatic 14C labeling capabilities, meeting pharma's demand for pure, traceable biologic tracer.

2

Expansion into Emerging Non-Pharma Application Markets

Non-pharma sectors (environmental science, advanced materials, agrochemicals) are increasingly requiring 14C tracers (e.g., for microplastic fate monitoring, polymer degradation tracing, agrochemical regulatory testing). Service providers can diversify revenue beyond pharmaceuticals by tailoring 14C synthesis services to these under-served markets, which face growing regulatory mandates for tracer-based data.

3

Regional Capacity Expansion in High-Growth APAC Markets

APAC (China, India, Southeast Asia) has surging drug R&D investment and regional policies (e.g., China's 2025 14C self-sufficiency mandate) favoring local service providers. Establishing regional 14C synthesis labs allows providers to capture local demand, avoid cross-border isotope transport delays, and align with regional regulatory standards (e.g., China's CFDA GMP requirements), reducing barriers for domestic biotech and pharma clients.

4

End-to-End GMP-Compliant 14C Service Packages

Global pharmaceutical clients need 14C-labeled compounds that meet FDA/EMA GMP standards + supporting regulatory documentation (e.g., batch records, purity certificates) for multi-region clinical trials. Service providers can differentiate themselves by offering integrated packages (14C synthesis, real-time QC, regulatory dossier preparation), reducing clients' administrative workload and accelerating their path to regulatory submissions.

Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025

Table 5. Carbon-14 Radiosynthesis Services Obstacles/Challenges to Industry Development

Obstacles/Challenges

Description

1

Regulatory & Multi-Region Compliance Complexity

Carbon-14 radiosynthesis services face fragmented, evolving regulations across regions (e.g., U.S. NRC licensing, EU Euratom radiation standards, China NNSA permits). Navigating overlapping rules for 14C handling, GMP alignment, and cross-border material transport increases administrative overhead, delays market entry, and raises compliance costs-especially for global service operators.

2

14C Isotope Supply Chain Fragility

14C precursors (e.g., [14C]-CO2, [14C]-labeled starting materials) are sourced from a small pool of global isotope producers. Supply disruptions (production outages, export/import restrictions, regional policy shifts) can cause material shortages, delay client R&D projects, and force providers to absorb higher procurement costs.

3

High Operational & Technical Barriers

Establishing radiation-shielded synthesis facilities, deploying automated high-throughput systems, and hiring certified radiochemists (specialized in site-specific 14C labeling for large molecules) requires significant capital investment (often $2M+ for lab setup). Technical complexity of biopharmaceutical 14C labeling also limits capacity for smaller service providers.

4

Radioactive Waste Management Constraints

14C-generated low-level radioactive waste requires disposal at licensed, region-specific facilities. Many regions (e.g., parts of APAC) have limited waste disposal capacity, leading to extended on-site storage, higher disposal fees, and increased regulatory scrutiny-adding operational friction and long-term cost burdens for service providers.

Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Carbon-14 Radiosynthesis Services market is segmented as below:
By Company
Eurofins
Revvity
Selcia
Novandi Chemistry
Almac
Pharmaron
WuXi AppTec
AM Chemicals
Nuvisan
Alfa Cytology
Headway
ViTrax

Segment by Type
GMP - Compliant Services
Non - GMP Services

Segment by Application
Medical
Chemical Research
Others

Each chapter of the report provides detailed information for readers to further understand the Carbon-14 Radiosynthesis Services market:

Chapter 1: Introduces the report scope of the Carbon-14 Radiosynthesis Services report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Carbon-14 Radiosynthesis Services manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Carbon-14 Radiosynthesis Services market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Carbon-14 Radiosynthesis Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Carbon-14 Radiosynthesis Services in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Carbon-14 Radiosynthesis Services competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Carbon-14 Radiosynthesis Services comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Carbon-14 Radiosynthesis Services market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Carbon-14 Radiosynthesis Services Market Outlook, In‐Depth Analysis & Forecast to 2032
Global Carbon-14 Radiosynthesis Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Carbon-14 Radiosynthesis Services Market Research Report 2026

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

This release was published on openPR.